XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS)

NAActive, not recruitingINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

October 10, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2029

Conditions
Heart FailureTransplant; Failure, Heart
Interventions
DEVICE

Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)

Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)

Trial Locations (20)

10016

NYU Langone Health, New York

10032

Columbia University Irving Medical Center/New York Presbyterian Hospital, New York

10467

Montefiore Medical Center, The Bronx

15213

University of Pittsburgh Medical Center, Pittsburgh

21201

University of Maryland Medical Center/University of Maryland, Baltimore, Baltimore

21287

Johns Hopkins Medicine, Baltimore

27710

Duke University, Durham

30322

Emory University, Atlanta

37232

Vanderbilt University, Nashville

43210

Ohio State University, Columbus

44195

Cleveland Clinic Foundation, Cleveland

60611

Northwestern Memorial Hospital, Chicago

63110

Washington University - Barnes Jewish Hospital, St Louis

68198

University of Nebraska Medical Center, Omaha

75390

UT Southwestern Medical Center, Dallas

90048

Cedars-Sinai, Los Angeles

90095

David Geffen School of Medicine at UCLA, Los Angeles

92037

University of California San Diego, La Jolla

94304

Stanford Medicine, Palo Alto

98195

University of Washington Medical Center, Seattle

All Listed Sponsors
lead

XVIVO Perfusion

INDUSTRY

NCT05881278 - XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS) | Biotech Hunter | Biotech Hunter